scPharmaceuticals Inc. (SCPH)
Automate Your Wheel Strategy on SCPH
With Tiblio's Option Bot, you can configure your own wheel strategy including SCPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SCPH
- Rev/Share 0.9302
- Book/Share -0.3968
- PB -11.7439
- Debt/Equity -2.4605
- CurrentRatio 3.8536
- ROIC -1.1073
- MktCap 248370078.0
- FreeCF/Share -1.2264
- PFCF -3.77
- PE -2.7294
- Debt/Assets 0.6535
- DivYield 0
- ROE -20.8611
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John Mohr - Senior Vice President of Clinical Development & Medical Affairs John H. Tucker - President, CEO, Principal Executive Officer & Director Rachael Nokes - Chief Financial Officer Steve C.
Read More
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Shares of scPharmaceuticals have lost 37% over the past 3 years and are down 11% in 2025. Furoscix's subcutaneous administration offers the potential to keep heart failure patients at home longer and cut down on hospital readmissions. Q1 seasonality is in the rearview mirror, with multiple tailwinds, including Medicare redesign and label expansion, to fuel growth going forward.
Read More
scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript
Published: March 19, 2025 by: Seeking Alpha
Sentiment: Neutral
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen Glen Santangelo - Jefferies Roanna Ruiz - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call.
Read More
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences:
Read More
About scPharmaceuticals Inc. (SCPH)
- IPO Date 2017-11-17
- Website https://www.scpharmaceuticals.com
- Industry Biotechnology
- CEO John H. Tucker
- Employees 162